Activating transcription factor 4 (ATF4) is a critical mediator of metabolic and oxidative homeostasis and cell survival. ATF4 is elevated in response to diverse microenvironmental stresses, including starvation, ER stress damages and exposure to toxic factors. Here we show that ATF4 expression fosters the malignancy of primary brain tumors (WHO grade III and IV gliomas) and increases proliferation and tumor angiogenesis. Hence, ATF4 expression promotes cell migration and anchorage-independent cell growth, whereas siRNA-mediated knockdown of ATF4 attenuates these features of malignancy in human gliomas. Further experiments revealed that ATF4-dependent tumor promoting effects are mediated by transcriptional targeting the glutamate antiporter xCT/SCL7A11 (also known as system Xc -). Thus, xCT is elevated as a consequence of ATF4 activation. We further found evidence that ATF4-induced proliferation can be attenuated by pharmacological or genetic xCT inhibition and ferroptosis inducers such as sorafenib, erastin and GPx4 inhibitor RSL3. Further, fostered xCT expression promotes cell survival and growth in ATF4 knockdown cells. Moreover, increased xCT levels ameliorate sorafenib and erastin-induced ferroptosis. Conversely, ATF4 knockdown renders cells susceptible for erastin, sorafenib and RSL3-induced ferroptosis. We further identified that ATF4 promotes tumor-mediated neuronal cell death which can be alleviated by xCT inhibition. Moreover, elevated ATF4 expression in gliomas promotes tumor angiogenesis. Noteworthy, ATF4-induced angiogenesis could be diminished by ferroptosis inducers erastin and by GPx4 inhibitor RSL3. Our data provide proof-of-principle evidence that ATF4 fosters proliferation and induces a toxic microenvironmental niche. Furthermore, ATF4 increases tumor angiogenesis and shapes the vascular architecture in a xCT-dependent manner. Thus, inhibition of ATF4 is a valid target for diminishing tumor growth and vasculature via sensitizing tumor cells for ferroptosis.
INTRODUCTION
Primary brain tumors are characterized by their specific microenvironmental niche containing pathological vessels and extracellular factors. These features promote angiogenesis and neuronal damage. 1, 2 These stress conditions can, in principle, also affect tumor cells. However, tumor cells are able to withstand these factors and remain metabolically adapted under such toxic conditions. The homeostatic adaptation is mediated via the so-called integrated stress response (ISR). 3 The ISR is critical for tumor survival and mediates its effects via protein synthesis reduction and enhanced activating transcription factor 4 (ATF4) expression. 4, 5 Activating transcription factors belong to the family of basic region leucine zipper proteins and operate as key transcriptional regulators. ATF4 in particular is a member of the CREB/ATF family and ubiquitously expressed in human organs and can be activated in response to various stress signals such as anoxia, hypoxia, endoplasmic reticulum stress, amino acid deprivation and oxidative stress. 6, 7 Stress-dependent expression of ATF4 causes adaptive responses in cells through regulating the expression of target genes. Noteworthy, ATF4-driven genes are mainly involved in amino acid synthesis, differentiation, metastasis, angiogenesis and drug resistance. [8] [9] [10] A general phenomenon is that elevated ATF4 expression is often observed in human tumor pathologies. 11, 12 Induction of the ISR requires ATF4 expression, and in this way tumor cells are believed to adapt and fit to their own created neurotoxic microenvironment. 7, 13 Highly elevated ATF4 expression is hypothesized to facilitate tumor progression. In fact, transcription of many essential genes involved in tumor cell proliferation is regulated by ATF4. 11, 14, 15 However, there are various effector genes induced by ATF4, 16, 17 whereas it is still not elucidated which of them are operational and necessary for the malignancy and tumor progression.
In this study, we found that human cells show increased signs of malignancy induced by concomitant ATF4 expression. Conversely, ATF4 inhibition can attenuate tumor growth. Further, we found that ATF4 upregulates xCT and elevated xCT expression can rescue the ATF4 deletion phenotype. Conversely, ATF4-induced tumor growth can be reverted by inhibition of xCT. On the basis of these findings, we further investigated the role of ATF4 in the brain microenvironment. Here we found that ATF4 promotes tumorinduced cell death, which can be attenuated by xCT inhibition. Moreover, fostered ATF4 expression increases tumor angiogenesis and vessel growth. Our results indicate that ATF4 acts as a promoter of cellular resistance towards ferroptosis and cytotoxic stress, thereby promoting tumor malignancy.
RESULTS
ATF4 fosters tumor cell growth First, we investigated the expression levels of ATF4 in a variety of human tumors (NIH Rembrandt Glioma database). We found that ATF4 is significantly elevated in malignant gliomas compared to non-transformed human brain tissue (Figure 1a ). Patients with high ATF4 expression levels displayed reduced overall survival time, while patients with low ATF4-expressing gliomas showed prolonged survival. (Figure 1b ). We also found that the levels of ATF4 mRNA were significantly upregulated in malignant glioma samples (Figure 1c ). Thus, gliomas with World Health Organization (WHO) classification grade II appeared with a two-fold ATF4 mRNA increase compared to normal brain samples, whereas most malignant gliomas (gliomas WHO°IV) exhibited a five-fold increase in ATF4 mRNA expression in comparison to normal brain tissue, respectively (Figure 1c ). Given the fact that the ATF4 gene is often genetically amplified and overexpressed in human malignant gliomas, we next investigated whether alteration of the transcriptional master regulator ATF4 affects cell morphology and cell death. First, we investigated the endogenous ATF4 mRNA levels in various glioma cells such as T98G, U87 and U251 ( Supplementary Figure 1a ). There we found that U87 cells show lower ATF4 expression compared to U251 and T98 wild-type glioma cells, whereas U251 showed highest ATF4 mRNA levels ( Supplementary Figure 1a ). This prompted us to continue our investigation with U87 and U251 cells. To gain insights into this, we expressed and repressed ATF4 in human cells (Figures 1d-f). ATF4 was stably transfected into U87 and U251 glioma cells (ATF4 OE ), and ATF4 was depleted in human cells by RNA interference (ATF4 KD ). ATF4 mRNA levels were detected by quantitative RT-PCR (Figure 1e -f). Further cytoskeletal immunoanalysis of human glioma cells revealed that ATF4 has a strong impact on the cell morphology ( Figure 1d ). ATF4-overexpressing (ATF4 OE ) cells display a polymorphic shape and their cell bodies are significantly bigger than in ATF4 KD and control cells ( Figure 1d ). In contrast, ATF4 KD cells appear generally smaller and show a spindle-like phenotype with maximal two membrane extensions ( Figure 1d ).
We further analyzed the cell proliferation and cell viability in ATF4 challenged cells. ATF4 OE glioma cells significantly increased cell growth compared to control cells (ctrl), whereas ATF4 rknockdown resulted in 40% growth reduction (Figures 2a and b). Hence, we investigated the impact of ATF4 expression on the cell cycle using BrdU and 7-AAD double staining. We compared the cell cycle profiles of controls, ATF4 OE and ATF4 KD cells, and found a significantly prolonged G2/M phase in ATF4 KD cells, whereas ATF4 OE cells showed~10% increase in the S phase ( Figure 2c ). Thus, a reduction in the proliferation rate of ATF4 KD cells could be caused due to an increased number of cells arrested in the G2/M phase.
Next, we investigated the anchorage-independent cell growth as a characteristic of oncogenic transformation and sign of malignancy. Quantification of colony formation in soft agar revealed that ATF4 overexpression resulted in a nearly 1.5-fold increase of colonies (Figures 3a and b ). In contrast, ATF4 suppression led to a two-fold reduction in colony numbers compared to control cells. (Figures 3a and b ). We continued characterizing the functional impact of ATF4 by studying the migration activity. For that, we cultured cells in a 3D spheroid matrix and monitored the invasive growth front (Figures 3c and d ). We observed that ATF4 OE cells migrated significantly faster than control cells (Figures 3c and d) . Conversely, ATF4 KD cells showed a low invasive growth pattern and ATF4 KD cells migrate significantly slower (Figures 3c and d) . Altogether, these results demonstrate that the ATF4 expression promotes glioma cell proliferation and migration.
ATF4 regulates xCT expression and glutamate secretion ATF4 is a potent inducer of ISR related and antioxidant gene expression. So far known transcriptional targets of ATF4 are xCT, HO-1, GPx1, SOD1 and others. 18 We tested, whether ATF4 can drive the expression and function of the glutamate antiporter xCT (SCL7a11/SCX) since xCT is a key player in brain tumor-induced intoxication of the microenvironment. 19, 20 We found that the levels of xCT mRNA were significantly increased in human malignant glioma specimens (Figure 4a ). Gliomas WHO°II appeared with a five-fold xCT mRNA increase compared to normal brain samples, whereas gliomas WHO°IV exhibited a 19-fold increase in xCT mRNA expression in comparison to normal brain tissue, respectively ( Figure 4a ). We then found that fostered ATF4 expression upregulated significantly the glutamate transporter xCT mRNA ( Figure 4b ). Moreover, increased xCT protein levels were accompanied by enhanced levels of ATF4 ( Figure 4c ). In contrast, ATF4 knockdown in human cells markedly reduced the xCT expression ( Figures 4b and c ). To validate this finding, we analyzed the extracellular glutamate and cystine levels secreted by cultured cells. Noteworthy, ATF4 OE cells secreted higher amounts of glutamate into the extracellular space ( Figure 4d ). In comparison, knockdown of ATF4 markedly reduced glutamate release and cystine uptake, presumably because of a decrease in intracellular glutamate available for transamination ( Figure 4d ). Given that xCT antiporter activity was determined by extracellular glutamate levels, we found elevated glutamate concentrations in ATF4 OE cells ( Figure 4d ). In contrast, knockdown of ATF4 significantly reduced the xCT transporter activity ( Figure 4d ).
Next, we examined whether the ATF4 target gene xCT is required for cell growth and proliferation. For this, we knocked down xCT, in particular in ATF4 OE and upregulated xCT expression in ATF4 KD cells ( Figure 4e ). Silencing of xCT expression by RNAi severely limited ATF4 OE cell growth below the levels of controls ( Figure 4e ). These findings could be confirmed in two independent human cell lines ( Figure 4e ). Interestingly, xCT expression in the background of ATF4 KD cells could fully rescue the growth and proliferation rates and reinstalled the levels of controls ( Figure 4e ). We further confirmed these findings by targeting xCT with a pharmacological approach (Figure 4f ). Interestingly, increased proliferation of ATF4 OE cells could be inhibited by xCT-specific inhibitors S-4-carboxy-phenylglycine (S-4CPG) and the clinically established drug sulfasalazine (SAS) ( Figure 4f ). 21 However, we found that xCT-specific inhibitors had no inhibitory growth effects on control cells, indicating that ATF4-driving cell growth is mediated by xCT ( Figure 4f ).
ATF4 expression induces acquired cell death resistance
We further investigated the mechanisms of ATF4-driven proliferation by studying cytotoxic efficacy of chemotherapeutics. The rationale comes from the fact that chemotherapeutic agents such as sorafenib and erastin are also xCT inhibitors. xCT is a major player in iron-dependent non-apoptotic cell death. 22 Proliferation assays and cell death monitoring revealed that 72 h after treatment sorafenib and erastin inhibited cell growth in a dose-dependent manner in controls (Figures 5a-f, Supplementary  Figure 1b 
ATF4 knockdown renders cells susceptible for ferroptosis
In order to investigate whether ATF4 affects the induction of ferroptosis, we analyzed the cell death mechanisms induced by sorafenib or erastin with and without iron chelation ( Figures 6 and 7 , Supplementary Figure 2 ). U87 cells were exposed to sorafenib (10 μM) and erastin (10 μM) for 18 h. We found that sorafenib robustly induced cell death in ATF4 KD 6c and 7c ). We further studied the effects of the glutathione peroxidase 4 (GPx4) inhibitor and ferroptosis inducer RSL3. 23 Consistent with these data, RSL3 treatment (at 0.1 μM) for 18 h significantly induced cell death and growth inhibitory effect in U87 cells, and this effect was strongest in ATF4 KD cells (Figures 8a and b ). Noteworthy, DFO and Fer-1 were both effective in preventing RSL3-induced ferroptosis in ATF4 OE and ATF4 KD U87 cells (Figures 8a and b ). We also observed that RSL3-induced cell death was associated with the accumulation of lipid peroxidation. Treatment of ATF4 KD U87 cells with RSL3 resulted in obvious increase in lipid peroxidation which was suppressed by co-treatment with DFO and Fer-1, whereas lipid peroxidation in ATF4 OE U87 cells increased slightly ( Figure 8c ). Altogether, the increase in intracellular reactive oxygen species Figure 8a ). In summary, these data show that sorafenib and erastin-induced cell death in ATF4 knockdown cells is associated with increased levels of ROS. ROS accumulation and subsequent cell death could be prevented by iron chelation of cellular iron uptake. Thus, our data evidence that ATF4 depletion renders cells susceptible for ferroptosis.
ATF4 overexpression increases neuronal damage through elevated xCT expression
To further investigate the functional relevance of ATF4 in glioma biology, we employed the vascular organotypic brain slice culture Quantification of the sub G1, G1, S and G2/M percentage in ATF4 OE , ATF4 KD , and respective control cells shown in (c). Statistical significance was calculated with Student's t-test (given are mean ± s.d., *Po 0.05; **Po0.01; ***Po0.001). BrdU incorporation and 7-AAD staining of ATF4 OE and ATF4 KD U87 cells was analyzed by flow cytometry (n = 3). ATF4 KD cells showed prolonged G2/M phase.
system termed VOGiM. 24, 25 The VOGiM approach allows monitoring cell invasion and neuronal cell death in an organotypic microenvironment reflecting the in vivo situation in the brain. We found that ATF4-overexpressing cells impaired the neuronal integrity and promoted neuronal cell death compared to ATF4 KD and control cells (Figures 9a and b ). In addition, ATF4 OE cells displayed increased tumor volume compared to controls (Figure 9c ). These data confirm the in vitro findings in single cells reported in Figure 3 . (c) Representative microscopic images of glioma spheroids on day 1, day 2, day 4 and day 6. (d) Quantification of spheroid area revealed that ATF4 OE cells migrate faster than control cells, but significantly slower in ATF4 KD cells. Statistical significance was calculated with Student's t-test (shown is mean ± s.d., n = 6, *P o0.05; **P o0.01; ***P o0.001). Due to the identification of ATF4-mediated xCT expression in glioma cells, we aimed at validating the role of ATF4-xCT pathway in the context of tumor-induced neuronal damage. For this, we treated primary neurons for 24 h with conditioned supernatants from ATF4 OE , ATF4 KD , ATF4 OE /xCT KD , ATF4 KD /xCT OE and control cells. Cell death staining revealed that conditioned media from Figures 9d and e ). To investigate whether such toxic effects are due to ATF4-mediated xCT expression, we tested conditioned media from ATF4 OE /xCT KD cells. We found that conditioned media from ATF4 OE /xCT KD cells was significantly weaker in inducing cell death compared to ATF4 OE cells (Figures 9d and e) . Similarly, neuronal cell death was increased when neurons were cultured in the presence of (Figures 9d and  e ). These results show that xCT plays also a critical role in executing the ATF4-mediated neuronal cell death.
ATF4 promotes tumor angiogenesis
We further analyzed whether ATF4 has an impact on other hallmarks of tumor microenvironmental processes. Therefore, we investigated peritumoral vessel formation as an independent malignant feature of gliomas. We monitored peritumoral vessels, which were surrounding gliomas. We found that ATF4 OE human glioma cells (U87 and U251) enhanced angiogenesis with increased tumor vessels and vessel length compared to control gliomas (Figures 10a and b) . Interestingly, ATF4 KD U251 cells showed reduced vessel nodes compared to controls (Figures 10a  and b ). These data indicate that ATF4 promotes tumor angiogenesis in gliomas. Next, we sought to investigate the potential role of ferroptosis in ATF4-driven angiogenesis. For this, we performed the VOGiM approach with ATF4 OE , ATF4 KD and control glioma cells were treated with erastin (10 μM), RSL3 (5 μM) and Fer-1 (0.5 μM). Five days after treatment, erastin and RSL3 significantly inhibited peritumoral vessel formation surrounding ATF4 KD and control gliomas ( Figure 11 ). In contrast, in ATF4 OE induced angiogenesis these angiogenesis reversing effects were lower but significant (Figures 11a and b) . Fer-1, however, attenuated erastin and RSL3suppressed angiogenesis of ATF4 KD and control gliomas (Figures 11a and b) . These data indicate that ATF4-induced angiogenesis can in part be reduced by erastin and RSL3mediated ferroptosis.
DISCUSSION
Here we present evidence that concomitant ATF4 expression promotes malignancy features of tumor cells such as cell growth, migration, angiogenesis and acquired chemo-resistance. One main downstream target could be identified as the glutamate antiporter xCT. Accumulating evidence has shown that xCT plays a critical role in developing and promoting malignancy of different cancer entities and in acquired chemo-resistance. 11, 20, 26 Moreover, xCT has been discovered as a key player in ferroptosis, a special form of iron-dependent cell death with therapeutic implications. 22, 27 Our results show that ATF4 conveys resistance to ferroptosis-mediated cell death. ATF4 is a critical mediator of metabolic and oxidative homeostasis. Also, ATF4 is implicated in cell survival and is elevated in response to ISR induced by diverse microenvironmental stresses, including starvation, ER stress damages and toxic exposure. 28 Here we found that ATF4 is critically involved in human cell proliferation, invasive tumor growth and angiogenesis.
The novelty of this report is the identification of the glutamate antiporter xCT as a major driver of ATF4 functions. In fact, xCT expression has an important role in determining the malignancy in gliomas and other cancer entities. 20, [29] [30] [31] Moreover, malignant gliomas induce neuronal degeneration and tumor-associated ATF4-driven angiogenesis and tumor-induced cell death D Chen et al brain edema in a xCT-dependent manner. 19 One major contributor to this glioma effects could be identified as the excitatory amino acid glutamate. 20 The amino acid transporter system x with the catalytic domain xCT has been shown to be vital in releasing glutamate into the extracellular space. Since tumor-derived glutamate release is one major factor contributing to tumorassociated neurodegeneration and subsequent brain swelling, xCT is a prime target for therapeutic interventions in gliomas. 32, 33 Thus, we addressed the question whether ATF4-induced alterations in cell growth and in the tumor microenvironment are causally linked to its transcriptional target xCT. 19 Our analyses revealed that siRNA-mediated xCT silencing in ATF4 OE cells can normalize cell proliferation. Moreover, deletion of ATF4 was sufficient in reducing proliferation and tumor growth. These effects could be abolished by reconstituting xCT in ATF4 KD cells, demonstrating that xCT operates through glutamate release as an ATF4 executor. In this respect, it is no surprise that ATF4 KD cells renders highly susceptible towards ferroptotic cell death. Our data reveal an important crosstalk of ATF4 and its downstream target xCT in gliomas. ATF4 confers ferroptosis resistance by its transcriptional regulation of xCT. Finally, our data demonstrate that targeting ATF4 inhibits key features of gliomas to form a deadly microenvironment. First, ATF4 expression in gliomas fosters tumor-induced cell death of adjacent normal brain cells. This is an important hallmark of gliomas, which determines its malignancy. 19, 20 Second, we found that ATF4 expression in gliomas increases tumor angiogenesis. Previous reports indeed showed that ATF4 is involved in tumor angiogenesis. 34, 35 Up to now, the angiogenesis-promoting effects of ATF4 were linked to increased HIF1a and VEGF expression. 36, 37 We could identify that xCT is a transcriptional target of ATF4 in glioma cells, and ATF4 promotes glioma cell growth through the functional activity of xCT, that is, increased glutamate secretion into the extracellular space. Thus, it is tempting to speculate that the angiogenesis-promoting effects are executed by xCT and that inhibition of xCT reduces these effects. Therefore, these findings give a mechanistic explanation for the recently reported observation of angiogenesis-promoting effect of glutamate. 38 Thus, our data revealed that ATF4 plays a key role in glioma malignancy features and many effects of ATF4 can be pinpointed to the regulation of xCT.
In conclusion, our results demonstrate that ATF4 is elevated in human gliomas and ATF4-induced proliferation can be attenuated by pharmacological or genetic xCT inhibition. Further, ATF4 promotes tumor-mediated neurotoxicity and tumor angiogenesis, which can be alleviated by xCT inhibition and ferroptosis inducers erastin and RSL3. Therefore, ATF4 represents a vital and promising target for anti-tumor strategies and ferroptosis induction in cancer cells.
Concerning the relevance of ATF4-induced chemo-resistancy a study from our laboratory was recently accepted for publication. In this study we provide clinical evidence that increased ATF4 can induce temozolomide (Temcat, Temodal) resistancy: Chen D, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N. The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas. doi:10.18632/oncotarget.17737.
MATERIALS AND METHODS

Cell culture
Human U87 and U251 glioblastoma cells were obtained from ATCC/ LGC-2397 (Wesel, Germany). Cells were cultured in Dulbecco's modified . ATF4-induced tumor angiogenesis can be diminished by inducing ferroptosis. (a) Control, ATF4 OE , ATF4 KD U87 cells (blue, white circle delineated) were implanted in rat brain slices and afterwards treated with erastin (10 μM) and RLS3 (5 μM) ± Fer-1 (0.5 μM) for 5 days. Erastin and RSL3 inhibited angiogenesis in control and ATF4 KD gliomas and this effects could be reversed by Fer-1. Vessels were stained for laminin (red) and nuclei were stained by Hoechst (blue). Scale bar represents 100 μm. (b) Quantitative analysis of vessel numbers and vessels lengths in peritumoral area. The data are presented as mean ± s.d. with n = 3 and P-values set as: *Po0.05; **Po0.01; ***Po0.001; n.s. no significance.
Eagle medium (Biochrom, Berlin, Germany) containing 10% fetal bovine serum (Biochrom, Berlin, Germany) with 100 U/ml penicillin, 100 μg/ml streptomycin (Biochrom, Berlin, Germany) and 1% L-glutamine (Gibco/ Invitrogen, Carlsbad, CA, USA). Primary rat neurons from newborn Wistar rat (P1-P4) brains were cultured in serum supplemented (10% fetal bovine serum) MEM medium, and additionally supplemented with 2% B27 agent (Invitrogen, Karlsruhe, Germany). Neurons and cell lines were cultured at 37°C with 5% CO 2 and saturated humidified.
Chemicals and reagents
Erastin was purchased from Hycultec GmbH (Beutelsbach, Germany). Sorafenib was purchased from LC Laboratories (Woburn, MA, USA). (1S, 3R)-RSL3 (RSL3) was purchased from Selleckchem BIOZOL (Eching, Germany). Erastin, Sorafenib and RSL3 were dissolved in DMSO under sterile conditions to concentration of 100 mM. Desferoxamine (DFO) and Ferrostatin-1 (Fer-1), Sulfasalazine (SAS), polyclonal rabbit to Laminin, propidium Iodide (PI), Hoechst 33342 and RNAase were bought from Sigma-Aldrich (Taufkirchen, Germany). Desferoxamine was dissolved in water under sterile conditions to a concentration of 50 mM. Ferrostatin-1 was prepared in 50% DMSO/water under sterile conditions to a final concentration of 50 mM. S-4-Carboxyphenylglycine was purchased from ACRIS Antibodies (Herford, Germany). Sulfasalazine was dissolved in ammonium hydroxide (400 mM) under sterile conditions at 200 mM. S-4-CPG was solved under sterile conditions in 1 M sodium hydroxide to concentration of 100 mM. Mouse monoclonal to ATF4 antibody (ab50546), rabbit polyclonal to xCT antibody (ab37185) and mouse monoclonal to GAPDH antibody (ab8245) was purchased from Abcam (Cambridge, UK). Polyclonal rabbit to phalloidin, 7-Aminoactinomycin (7-AAD), BODIPY C11 (581/591) and Alexa Fluor IgG secondary antibodies were purchased from Life Technologies (Darmstadt, Germany). Polyclonal rabbit to GFAP was purchased from Dako (Glostrup, Denmark). Mouse monoclonal to β-III-tubulin and secondary antibodies used for Western blotting were obtained from Promega (Madison, WI, USA). Roti-fect was obtained from Roth (Karlsruhe, Germany).
Database analysis
The web-based human cancer microarray database NIH/NCI Rembrandt data portal (formerly hosted at https://rembrandt.nci.nih.gov, now moved to http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3073/ and Georgetown University at https://gdoc.georgetown.edu/gdoc/) and Oncomine (Compendia Biosciences; Ann Arbor, MI, USA; www.oncomine.org) was used to analyze the ATF4 mRNA expression in different malignant brain tissues. Details of the general standardized normalization techniques and statistical calculations can be found on the Oncomine website (https:// www.oncomine.com).
Construction of expression plasmids and cell culturing
The full-length complementary DNA (cDNA) of ATF4 and xCT (human ATF4 GenBank accession no. NM_001675.4 and human xCT GenBank accession no. AF252872) were amplified from different DNA templates using a standard PCR-based cloning strategy. PCR products were cloned and ligated into the BglⅡ-EcoRⅠ site of the peGFP-N1 vector and the peGFP-C1 (Takara, Heidelberg, Germany), respectively. Cells were transfected with ATF4 or xCT expression plasmid using Roti-fect according to the manufacture's instruction. After 5 days, the culture media was refreshed containing 700 μg/ml Geneticin sulfate 418 (G418; Sigma, St.Louis, MO, USA) for antibiotic selection. After 3 weeks of culturing the selected antibiotics, survival-transfected cells were collected. Stabled-transfected cells were used maintained in 500 μg/ml Geneticin sulfate 418.
Construction of shRNA plasmids and cell transfection
Off-target effects of RNAi were minimized by choosing three 19-mer short interfering RNAs targeting the human ATF4 gene, xCT gene according to the critera of Ui-Tei et al. The selected ATF4 shRNA, xCT shRNA and a scrambled sequence with no homology to any known human genes were synthesized and ligated into the BglII/HindIII sites of pSuperGFP-neo plasmid (OligoEngine) according to the manufacturer's instruction. ATF4 shRNA, xCT shRNA and srambled shRNA were introduced into glioma cells by transfection with Rofi fect. Cells stably depleted of ATF4 or xCT were obtained by selection with 700 μg/ml G418 as described above.
Cell viability assays and inhibitor studies
Cells were seeded onto 96-well plates (8000 cells per 100 μl per well) and were allowed to attach overnight. For inhibitor studies, cells were treated with indicated concentration for sorafenib, erastin or RSL3 after plating for 12 h. Cell viability was assessed at different time points after treatment (usually 72 h, unless stated otherwise) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT, 5 mg/ml in phosphate-buffered saline; Roth, Karlsruhe, Germany) for 2-3 h. Afterwards, the formazan crystals were then lysed with 100 μl acidic isopropanol and the absorbance of the obtained solutions was determined at 570 nm using TECAN F50 (Crailsheim, Germany) software.
Colony-forming assay
Glioma cells were suspended in 0.5% agar and seeded at~1000 cells per well of a six-well plate on a preformed 1% agar layer as described in detail. 39 Cells were cultured at 37°C in 5% humidified CO 2 for 3 weeks and then washed twice with PBS, methanol-fixed for 15 min, and stained with 0.5% crystal violet for 15 min at room temperature. The colony is defined to consist of at least 50 cells.
Cell morphology analysis
Three dimensional spheroid migration assay A total of 100 000 cells per spheroid were packaged in 100 μl mixture with 32% methylcellulose solution and 68% culture medium. Cell packages were dropped on the petri dishes and reversely cultured (37°C, 5% CO 2 , standard humidified conditions) for 12 h so that the cell packages were located with all the cells aggregate to the top and formed spheroid. 25, 39 Afterwards the spheroid was moved to the 48-well plate and kept culturing with medium. After 12 h, the spheroid attached to the bottom of the well and the cells migrate, and the pictures of spheroids were taking on the time points day 1, day 2, day 4 and day 6 by Olympus IX71 microscope, and the cells growth area of the spheroid were measured by Image J software (NIH, Bethesda, USA).
Cell cycle analysis
A total of 200 000 cells per well were seeded in 6-well plate and drug treatment was applied for 24 and 72 h. 41 Cells and media supernatants were collected as described before. 29 Briefly, cells were washed with PBS and fixed with 70% ethanol solution overnight at 4°C. Fixed cells were washed twice with PBS solution and afterwards resuspended in Hypotonic lysis buffer (0.1% sodium citrate, 0.1% Triton X-100, 100 μg/ml RNAse) for 20 min. Cell cycle analyses were performed within 2 h after adding 7-AAD (7-aminoactinomycin D) by Flow Cytometer BD FACSCanto II (BD Bioscience, Heidelberg, Germany). Analyses were carried out with FlowJo Software 7.6 (Ashland, OR, USA). A minimum of 10 000 cells were counted and analyzed per condition.
BrdU incorporation assay
For BrdU incorporation assay, cells were exposed to medium containing 10 μM 5-bromo-2′-deoxyuridine (BrdU) for 30 min. The cells were then collected, washed to remove unbound BrdU and fixed in 70% ethanol for 45 min on ice. Subsequently, cells were permeabilized with 2 N HCl/Triton X-100 to denature the DNA for 30 min, and incubated with 100 μg/ml RNAse for 30 min. Secondary Alexa Fluor 647-conjugated IgG was added for 30 min at 37°C, followed by counterstain with 7-AAD. Cellular fluorescence was measured by Flow Cytometer BD FACSCanto II (BD Bioscience). Analyses were carried out with FlowJo Software 7.6.
Cell death analysis by 7-AAD and Annexin V assay Drugs were applied for 24 and 72 h. After treatment, the Annexin V/7-AAD was assayed (BD Biosciences, Germany) for cell death analysis. Briefly, fresh cell preparations were incubated with 1X Annexin binding buffer and Annexin V/PE (5 μl)-conjugated primary antibody and 7-AAD (5 μl) for 15 min on ice. After incubation, cells were transferred to FACS tubes and analyzed by Flow Cytometer BD FACSCanto II (BD Bioscience, Heidelberg, Germany). A minimum of 10 000 cells were counted and analyzed per condition. Analyses were carried out with FCS Express 5 Demo Software.
Staining for lipid peroxidation in cells by flow cytometry 200 000 cells/well were seeded in 6-well plate. The next day, culture media was replaced with media containing sorafenib (10 μM), erastin (10 μM) or RSL3 (0.1 μM)+/ − deferoxamine (DFO, 100 μM) and+/ − ferrostatin-1 (Fer-1, 0.5 μM) for 18 h (RSL3, 8 h). After incubation, cells were harvested by trypsinization, washed and resuspended in 500 μl PBS containing BODIPY C11 (2 μM) in FACS tubes. Flow Cytometer BD FACSCanto II was used for the follow cytometer analysis. A minimum of 10 000 cells were counted and analyzed per condition. Analyses were carried out with FCS Express 5 Demo Software.
Metabolic profiling of tumor cells
Unless indicated, all cultures contained 10 mM glucose and 2-4 mM glutamine. To measure consumption and secretion of amino acids from glioma cells, cells were incubated in DMEM without glutamine for 24 h. 21 The supernatants were collected and measured by using high performance liquid chromatography (HPLC). Profiles of amino acids were performed by ion-exchange chromatography and post-column ninhydrin derivatization technique using Biochrom 30+ (Laborservice Onken, Gründau, Germany). In brief, 100 μl of each sample was deproteinized with 100 μl of 10% sulphosalicylicacids and 20 μl supernatant was then loaded into a cationexchange resin-filled column.
VOGIM assay and angiogenesis analysis
Organotypic brain slice cultures were conducted with 5-days-old Wistar rats. Tissues were prepared and maintained as previously described. 24, 42 In brief, at day 0, brains were prepared and isolated under ice-cold conditions. Cerebrum was cut into 350 μm thick horizontal slices on a Leica VT 1000S vibratome (Bensheim, Germany) and brain slices were thereafter transferred onto culture plate insert membrane dishes with a pore size of 0.4 μm (GreinerBioOne, Frickenhausen, Germany). Slices were cultured in six-well culture dishes (GreinerBioOne) containing 1.2 ml culture medium (MEM-based HBSS medium, for details see 24, 42 ). The slices were cultured in humidified atmosphere (35°C, 5% CO 2 ) and washed with 1.2 ml PBS and a full culture medium exchange was performed. At day two, 0.1 μl of the cell-medium-suspension (containing 10 000 con U87, ATF4 KD U87 or ATF4 OE U87 cells) was placed onto the temporal cortex of the slice by using a 1-μl-Hamilton-syringe. The medium was regularly changed every other day over a course of 7 days. Propidium Iodid (PI) (Sigma) staining was performed on day 5, incubating slices with 1 μg/ml PI for 15-20 min and then wash slices and 6-well plates with PBS. After washing with PBS, complete medium exchange followed. For induction of ferroptosis, brain slices were treated with media containing erastin (10 μM), RSL3 (5 μM)+/ − Fer-1 (0.5 μM) for 5 days. On day 7, all the slices were fixed with Immunfixative (4% PFA and picric acid) and stained with anti-laminin-antibody (1:250) for vessel analysis as detailed in Fan et al. 38 The number of tumor vessels was quantified by counting the number of vessels which grew into the tumor as described previously. 24 
Statistical analysis
The data are expressed as mean ± s.d. taken from at least three independent experiments, and compared with unpaired Student t-test or Mann-Whitney test where appropriate using SPSS statistics 17.0 software (IBM, Armonk, NY, USA). P-values of Po0.05, **Po0.01; ***P o0.001 were considered as statistically significant.
